<SEC-DOCUMENT>0001104659-21-124612-index.html : 20211008 <SEC-HEADER>0001104659-21-124612.hdr.sgml : 20211008 <ACCEPTANCE-DATETIME>20211008161437 ACCESSION NUMBER: 0001104659-21-124612 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 6 FILED AS OF DATE: 20211008 DATE AS OF CHANGE: 20211008 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-260146 FILM NUMBER: 211315456 BUSINESS ADDRESS: STREET 1: 25-28 NORTH WALL QUAY CITY: DUBLIN STATE: L2 ZIP: D01 H104 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 414 COMMERCE DRIVE STREET 2: STE 120 CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 </SEC-HEADER> <DOCUMENT> <TYPE>S-1 <SEQUENCE>1 <FILENAME>tm2129373-1_s1.htm <DESCRIPTION>S-1 <TEXT> Document 1 - file: tm2129373-1_s1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.1 <SEQUENCE>2 <FILENAME>tm2129373d2_ex5-1.htm <DESCRIPTION>EXHIBIT 5.1 <TEXT> Document 2 - file: tm2129373d2_ex5-1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.43 <SEQUENCE>3 <FILENAME>tm2129373d2_ex10-43.htm <DESCRIPTION>EXHIBIT 10.43 <TEXT> Document 3 - file: tm2129373d2_ex10-43.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-23.1 <SEQUENCE>4 <FILENAME>tm2129373d2_ex23-1.htm <DESCRIPTION>EXHIBIT 23.1 <TEXT> Document 4 - file: tm2129373d2_ex23-1.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>lg_nabriva-4c.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 5 - file: lg_nabriva-4c.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>tm2129373d2_ex5-1img001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 6 - file: tm2129373d2_ex5-1img001.jpg
</DOCUMENT> </SEC-DOCUMENT>